Issues & Trends

MKElectron Reports Cumulative Operating Profit of 53.5 Billion Won for the First Three Quarters… All-Time High

Growth Continues Despite Exchange Rate Fluctuations

Kwon Oh Seok
2026-11-13 17:58:14
[Edaily Reporter Kwon Oh Seok ] MKElectron(033160), a company specializing in semiconductor packaging materials, has demonstrated its growth momentum by setting a new record for cumulative operating profit through the third quarter of this year. Analysts attribute this performance to increased shipments of its core materials and the full-scale launch of new business revenue streams, which drove both earnings stability and growth despite internal and external challenges such as sharp exchange rate fluctuations and the sale of an affiliate.
(Photo courtesy of MKElectron)

According to industry sources on the 13th, MKElectron’s cumulative consolidated revenue for the first three quarters of this year totaled 1.3491 trillion won, with operating profit reaching 53.5 billion won. Compared to the same period last year, revenue rose by approximately 49% and operating profit surged by 894%, setting a new all-time high on a cumulative basis since the company’s founding.
Looking at the details, standalone third-quarter performance slowed slightly compared to the previous quarter due to the burden of raw material and inventory revaluation caused by a sharp rise in exchange rates, as well as the impact of the sale of its subsidiary Dongbu Entech, which resulted in its exclusion from the consolidated financials. However, sales volumes of semiconductor packaging materials—such as bonding wire and solder balls, the company’s core cash cows—continued to trend steadily upward, underpinning the company’s fundamental strength. The expansion of high-value-added products, efforts to streamline production, and the growth of the Chinese subsidiary driven by the expansion of the local semiconductor market in China also contributed to improved profitability.
The company explained that the upward trend in earnings is expected to continue into the fourth quarter, making it highly likely that annual cumulative operating profit will also set a new record. This is because demand for its core materials remains robust, while cost pressures stemming from exchange rate volatility are gradually easing. Furthermore, if the gain from the sale of Dongbu HANTECH LTD. is reflected in the fourth-quarter results, annual net income is expected to significantly exceed market expectations. In effect, the company is killing two birds with one stone by improving its financial structure and securing cash liquidity through the divestiture of non-core assets.
Efforts to secure next-generation growth engines and mid- to long-term growth drivers are also proceeding smoothly. The palladium alloy (Pd Alloy) business—which produces materials for test sockets—surpassed cumulative sales of 10 billion won last July and, having recently secured new overseas customers, began generating its first overseas sales starting in the fourth quarter. To meet growing global demand, the company is considering expanding its Pd Alloy production facilities and is investing to increase its plated wire production capacity by approximately 50% compared to this year, with the goal of completing the expansion in the first half of next year.

Economy

Corporation

IT·Science

Economy

"Aftermath of the Jensen Huang Scandal… U.S. to Impose Strict Export Controls on China"

“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
2026-11-13 17:31:12

Corporation

"Baek Jong-won Risk" Eases… The BORN Korea Narrows Third-Quarter Loss

As the controversy surrounding Baek Jong-won, CEO of The BORN Korea, begins to subside, the company’s net loss for the third quarter of this year has narrowed significantly. The quarterly operating lo…
2026-11-13 18:23:44

IT·Science

HANDOK Inc.: Partner Company’s Rare Hypoglycemia Treatment Set to Draw Attention This Year… Results of External Collaboration Put to the Test

Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…
2026-11-13 15:42:02